HEALTHCARE severe diseases in two therapeutic areas : Central Nervous System and Immunology . UCB also has a selective presence in primary care .
As severe diseases are treated by a relatively small number of specialists , UCB can have a close relationship and regular dialogue with physicians and their patients — an essential ingredient for understanding and addressing the daily physical and social symptoms of these diseases .
Severe diseases also require a smaller sales force , so more resources can be devoted to R & D and other functions .
The Company also maintains a strong yet selective presence in primary care ( e . g . allergy and cardiovascular ) to support specialist products that are administered by primary care physicians .
Furthermore , UCB combines biology and chemistry to make major breakthroughs . By integrating their expertise in large , antibodybased molecules and small , chemically-derived molecules , they can offer families with severe diseases and their specialist physicians : The efficacy of largemolecule ‘ new biological entities ’ ( NBEs ), such as Cimzia ®; the convenience and cost-effectiveness of small , ‘ new chemical entities ’ ( NCEs ), such as Keppra ®, Neupro ® or Vimpat ®; and the advantages of both to produce extraordinary breakthroughs .
UCB ’ s pioneering A2HiT™ project , which is using the Company ’ s leading antibody research to design more effective novel chemical entities , is one of the most exciting examples of how they are capitalising on the synergies between biology and chemistry .
Because UCB understands that the complexities of severe diseases are beyond the expertise and resources of a single organization , they partnering with the leaders in the pharmaceutical industry . From research and development to marketing and supply chain , we have joined forces with organisations such as Amgen ( R & D - anti-sclerostin for bone loss disorders ), sanofi-aventis ( Marketing - Xyzal ®, antihistamine ) and Lonza ( Manufacturing - Cimzia ® for Crohn ’ s disease and rheumatoid arthritis ). www . ucb . com / 103